摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(苄氧基)-3-溴苯甲醛 | 69455-12-5

中文名称
4-(苄氧基)-3-溴苯甲醛
中文别名
——
英文名称
4-benzyloxy-3-bromobenzaldehyde
英文别名
3-bromo-4-benzyloxybenzaldehyde;4-Phenylmethoxy-3-bromobenzaldehyde;4-(Benzyloxy)-3-bromobenzaldehyde;3-bromo-4-phenylmethoxybenzaldehyde
4-(苄氧基)-3-溴苯甲醛化学式
CAS
69455-12-5
化学式
C14H11BrO2
mdl
MFCD02629356
分子量
291.144
InChiKey
LMAYCCCBNRUZPC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    96-99°
  • 沸点:
    406.3±30.0 °C(Predicted)
  • 密度:
    1.441±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.071
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2913000090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312+P330,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:3f0d7a4aadb19c63d6fe913f46d37fc0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-(Benzyloxy)-3-bromobenzaldehyde
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Benzyloxy)-3-bromobenzaldehyde
CAS number: 69455-12-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H11BrO2
Molecular weight: 291.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Versatile Routes to Marine Sponge Metabolites through Benzylidene Rhodanines
    摘要:
    The first total synthesis of the marine natural products Psammaplin C and Tokaradine A is described. Benzylidene rhodanines were utilized as versatile intermediates toward the synthesis of seven brominated marine sponge metabolites through the optimization of protection group strategies. Spermatinamine demonstrated good inhibition of all cancer cell lines tested, in particular the leukemia K562 and colon cancer HT29 cell lines.
    DOI:
    10.1021/ol303057a
  • 作为产物:
    描述:
    参考文献:
    名称:
    Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
    摘要:
    提供了用于预防和治疗由副粘病毒科的Pneumovirinae亚科病毒引起的感染以及与这类感染相关的疾病的化合物、组合物和方法。
    公开号:
    US06495580B1
点击查看最新优质反应信息

文献信息

  • Linear diarylheptanoids as potential anticancer therapeutics: synthesis, biological evaluation, and structure–activity relationship studies
    作者:A. F. M. Motiur Rahman、Yang Lu、Hwa-Jong Lee、Hyunji Jo、Wencui Yin、Mohammad Sayed Alam、Hyochang Cha、Adnan A. Kadi、Youngjoo Kwon、Yurngdong Jahng
    DOI:10.1007/s12272-018-1004-8
    日期:2018.12
    detrimental action of the drug toward the intestinal flora, a series of linear diarylheptanoids (LDHs) were designed and synthesized in 7 steps with good-to-moderate yields. All synthesized compounds were evaluated for their antibacterial, antiproliferative, and topoisomerase-I and -IIα inhibitory activity. Overall, all compounds showed little to no activity against the bacterial strains tested. Most of the
    为了开发有效的抗癌疗法,对癌细胞具有更大的选择性并减少副作用,例如由于药物对肠道菌群的有害作用引起的催吐作用,设计并分 7 个步骤合成了一系列线性二芳基庚烷 (LDH)产量良好至中等。评估了所有合成化合物的抗菌、抗增殖和拓扑异构酶-I 和-IIα 抑制活性。总体而言,所有化合物对所测试的细菌菌株几乎没有活性。大多数合成的化合物对人乳腺癌细胞系(T47D)显示出良好的抗增殖活性;具体而言,化合物 6a、6d、7j 和 7e 的 IC50 值分别为 0.09、0.64、0.67 和 0.99 μM。在测试的化合物中,7b 抑制了 topo-I 9。在 100 μM 的浓度下,3%(喜树碱 68.8%)、7e 和 7h 分别抑制了 38.4% 和 47.4%(依托泊苷 76.9%)的 topo-IIα。这些结果表明,可以通过减少对不同微生物的抑制作用来提高对癌细胞的选择性,从而获得一组有前景的抗癌药物。
  • Synthesis of Aromatic Carboxylic Acids by Carbonylation of Aryl Halides in the Presence of Epoxide-Modified Cobalt Carbonyls as Catalysts
    作者:V. P. Boyarskii、T. E. Zhesko、S. A. Lanina
    DOI:10.1007/s11167-005-0619-y
    日期:2005.11
    A new procedure was developed for synthesis of aromatic and heteroaromatic acids and their derivatives (esters, salts) by carbonylation of the corresponding aryl halides. The acids are selectively formed in a high yield under very mild conditions. Highly active catalytic systems, base-containing alcoholic solutions of cobalt carbonyl modified with epoxides, were used to activate aryl halides.
    开发了一种新方法,用于通过相应的芳基卤化物的羰基化合成芳族和杂芳族酸及其衍生物(酯,盐)。在非常温和的条件下可以高产率选择性地形成酸。高活性的催化体系(用环氧化物改性的含羰基钴的含碱醇溶液)用于活化芳基卤化物。
  • Facile and divergent optimization of chromazonarol enabled the identification of simplified drimane meroterpenoids as novel pharmaceutical leads
    作者:Xia Wang、Nvdan Hu、Wenlong Kong、Baoan Song、Shengkun Li
    DOI:10.1016/j.ejmech.2021.113912
    日期:2022.1
    antitumor activities. (+)-Albaconol, (+)-neoalbaconol, and two (+)-yahazunol isomers (24 and 25) proved to be the novel pharmaceutical leads. The probable macromolecular targets were estimated to deliver new information about the biological potentials resident in (+)-yahazunol relevant products. This work also featured the first synthesis of (+)-albaconol and (+)-neoalbaconol, the first biological exploration
    drimane 对苯二酚的多样性通过 (+)-chromazonarol 相关天然产物、异构体和类似物的简便构建显着扩大,以发现新的药物先导物。(+)-chromazonarol 相关(非)天然产物的构效关系通过可编程合成和生物活性引导筛选的协同作用进行描述。(+)-chromazonarol 的第一次不同衍生表明羟基是抗真菌作用不可侵犯的要求。(+)-yahazunol 的精确修饰表明羟基的位置对于抗真菌和抗肿瘤活性都至关重要。(+)-Albaconol、(+)-neoalbaconol 和两种 (+)-yahazunol 异构体 ( 24和25) 被证明是新的药物先导。估计可能的大分子靶标可提供有关 (+)-yahazunol 相关产品中存在的生物潜力的新信息。该工作还首次合成了 (+)-albaconol 和 (+)-neoalbaconol,首次对 (+)-dictyvaric acid
  • [EN] BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS<br/>[FR] DÉRIVÉS DE BENZOCYCLOBUTANE UTILES EN TANT QUE MODULATEURS DOUBLES DE SGLT1/SGLT2
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2018089449A1
    公开(公告)日:2018-05-17
    The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.
    本发明涉及苯并环丁烷生物,含有它们的药物组合物以及它们在治疗由SGLT活性调节的疾病和症状中的应用,更具体地说是双重SGLT1/2活性。更具体地说,本发明的化合物在治疗例如II型糖尿病、X综合征以及与这些疾病相关的并发症和症状中是有用的。
  • [EN] 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE<br/>[FR] DÉRIVÉS DE 2-(HÉTÉRO)ARYLBENZIMIDAZOLE ET D'IMIDAZOPYRIDINE COMME INHIBITEURS DE L'ASPARAGINE MÉTHYLTRANSFÉRASE
    申请人:CANCER THERAPEUTICS CRC PTY LTD
    公开号:WO2014128465A1
    公开(公告)日:2014-08-28
    Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from:, a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are β to one another; L1 is selected from: (i)A1-O-CH2-A2; (ii)A1-CH2-O-A2; (iii)A1-C(=O)-NH-A2; (iv)A1-CH(OH)-A2; (v)A1-CH2-NH-C(=O)-A2; (vi) A1-S-CH2-A2; (vii)A1- CH2-S-A2; (viii)A1-CH2-A2; and (ix)A1-CH(CH3)-O-A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.
    取代苯并咪唑和3H-咪唑并[4,5-b]吡啶或式I:其中X和Y分别选自:(i) N和N;和(ii) N和CR4;A2选自:,一个含有2或3个环异原子的C5杂芳基团,其中与L1和核心的键是β相对于彼此的;L1选自:(i)A1-O-CH2-A2;(ii)A1- -O-A2;(iii)A1-C(=O)-NH-A2;(iv)A1-CH(OH)-A2;(v)A1- -NH-C(=O)-A2;(vi) A1-S- -A2;(vii)A1- -S-A2;(viii)A1- -A2;和(ix)A1-CH(CH3)-O-A2;A1是苯基,可选择性地被F或CF3取代;它们作为药物的用途,特别是在治疗癌症和血红蛋白病中。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯